Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Depomed initiates phase I DM-1992 trial in Parkinson's disease

Feb. 18, 2009

Galantamine beneficial in elderly patients with severe Alzheimer's disease

Feb. 18, 2009

Clofazimine acts on target implicated in autoimmune diseases

Feb. 18, 2009

Otsuka claims new neuroprotectants and their use in Parkinson's disease

Feb. 18, 2009

NeuroSearch enters ion channel target development alliance with Lilly

Feb. 17, 2009

BioAlliance seeks E.U. MAA for fast-dissolving ondansetron

Feb. 17, 2009

Bristol-Myers Squibb reports new SERT inhibitors and/or NK1 receptor antagonists

Feb. 17, 2009

New BACE inhibitors reported in recent Boehringer Ingelheim patent

Feb. 17, 2009

Oral laquinimod granted FDA fast track designation for multiple sclerosis

Feb. 16, 2009

Octapharma commences phase II study of Octagam in Alzheimer's disease

Feb. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...